NEUROPROTECTIVE POTENTIAL OF ALOGLIPTIN IN LIPOPOLYSACCHARIDE INDUCED EXPERIMENTAL MODEL OF PARKINSON’S DISEASE

Abstract

AbstractBackgroundParkinson’s disease is a hypokinetic movement disorder characterized by selective loss of dopaminergic neurons in the substantia nigra. Dopaminergic degeneration of neurons is considered to be due to oxidative stress, neuroinflammation, mitochondrial dysfunction etc. Thus therapies that could alter all the pathologies linked with the disease and produces less or minimal side effects may work as better therapeutic target than the existing one.MethodThe intranigral LPS (5µg/μl) administration was used to induce PD like symptoms in rats. LPS‐infused rats were treated with alogliptin (10, 20 and 40 mg/kg/day/p.o.) for 21 days. Behavioral parameters and body weight analysis were performed on weekly basis to examine the movement disabilities in rats. On 21st day, animals were sacrificed; biochemical and histological assessment was done to evaluate role of alogliptin in LPS‐infused rats.ResultIt has been observed that Alogliptin at significant dose level attenuates movement disabilities in LPS induced in PD rats. Alogliptin significantly reduces malondialdehyde, nitrites levels and raises glutathione levels. These suggest that neuroprotective action of alogliptin is due to its anti‐oxidant activity. Moreover, histomorphological assessment confirms the neuroprotective activity of alogliptin.ConclusionAlogliptin has neuroprotective potential and observed increment in the motor activity of LPS‐infused rats following alogliptin treatment may be due to its antioxidant potential and ability to prevent the morphological alterations in brain cells.